Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Precision BioSciences Inc DTIL

Healthcare Biotechnology
Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene... see more

Recent & Breaking News (NDAQ:DTIL)

Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company's Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate

Business Wire January 6, 2023

Precision BioSciences Presents Analysis of Azer-Cel, Allogeneic CAR T Product Attributes Related to In Vivo Pharmacokinetics, Pharmacodynamics, and Clinical Outcomes at 2022 American Society of Hematology Annual Meeting

Business Wire December 10, 2022

Precision BioSciences Announces Change to its Board of Directors

Business Wire November 10, 2022

Precision BioSciences Reports Third Quarter 2022 Financial Results and Provides Business Update

Business Wire November 8, 2022

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire November 4, 2022

Precision BioSciences Announces Data Presentation on Effective Cell Dose and Functional Attributes of CD19 Allogeneic CAR T, Azer-Cel, at the Upcoming 2022 American Society of Hematology (ASH) Annual Meeting

Business Wire November 3, 2022

Precision BioSciences to Report Third Quarter 2022 Financial Results on November 8, 2022

Business Wire November 2, 2022

Precision BioSciences Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

Business Wire October 26, 2022

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress

Business Wire October 11, 2022

Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit

Business Wire September 22, 2022

Precision BioSciences to Participate in Upcoming H.C. Wainwright 24th Annual Global Investment Conference

Business Wire September 7, 2022

Precision BioSciences Announces Senior Leadership Organizational Changes

Business Wire September 2, 2022

Precision BioSciences Reports Second Quarter 2022 Financial Results and Provides Business Update

Business Wire August 8, 2022

Precision BioSciences to Report Second Quarter 2022 Financial Results on August 8, 2022

Business Wire August 1, 2022

Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Business Wire July 25, 2022

Precision BioSciences Announces Closing of Underwritten Offering of Common Stock

Business Wire June 27, 2022

Precision BioSciences Announces $50 Million Offering of Common Stock

Business Wire June 21, 2022

Precision BioSciences Announces In Vivo Gene Editing Collaboration with Novartis to Develop Potentially Curative Treatment for Disorders Including Sickle Cell Disease

Business Wire June 21, 2022

Precision BioSciences Provides Update on Allogeneic CAR T Programs and Path Forward with Its Lead PBCAR0191 Candidate for CAR T Relapsed Patient Population

Business Wire June 8, 2022

Precision BioSciences to Provide an Update on its Ongoing Allogeneic CAR T Programs via Hosted Virtual Webcast and Conference Call on Wednesday, June 8, 2022

Business Wire June 3, 2022